Targeting Tobacco Cessation During Treatment for Cannabis Use Disorders

Status Completed

Clinical Trial Summary

This project aims to develop and test an intervention for the simultaneous treatment of cannabis use disorders and tobacco smoking. This is important because over 50% of adults seeking treatment to help stop cannabis use also smoke tobacco regularly, which decreases their chance for a successful treatment outcome and increases adverse acute and long-term psychosocial and health consequences. The proposed treatment will integrate existing computer-based behavioral interventions for cannabis and tobacco and use nicotine replacement medications to improve outcomes in this difficult to treat clinical population.

Clinical Trial Description

Approximately 50% of persons seeking treatment for cannabis-use disorders (CUDs) regularly smoke tobacco. Combining tobacco with cannabis has become a common method of smoking cannabis. Similarities of use, and using together, can make quitting difficult. Stopping tobacco simultaneously with cannabis may be beneficial. Little scientific information currently addresses how to best target tobacco smoking during treatment for CUDs. Our long-term goal is to develop an effective protocol for intervening in tobacco smoking without changing cannabis outcomes. A two-phase, Stage 1 therapy development project will accomplish the following: First, a treatment protocol and manual will be developed that integrates a tailored intervention for tobacco smoking with an intervention for CUD (Aim 1). Utilization of web-based counseling programs will standardize delivery of the intervention and foster eventual dissemination. A pilot study will provide an initial test of acceptability and feasibility. Second, a Stage 1, proof-of-concept study will compare this intervention to one that targets CUD only (Aim 2). The hypotheses assert that the intervention (1) will be accepted by the majority of eligible participants (2) will result in more tobacco quit attempts and rates than the CUD-only treatment; and (3) will not adversely affect cannabis outcomes. Last, the project will evaluate the potential of specific moderators of outcomes to predict outcomes and inform subsequent treatment development efforts (Aim 3). If the hypotheses were confirmed, dissemination of this protocol would reduce adverse psychosocial and health consequences of tobacco or cannabis dependence. Findings will inform future development of prevention and intervention strategies. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01834794
Study type	Interventional
Source	Dartmouth-Hitchcock Medical Center
Contact
Status	Completed
Phase	N/A
Start date	March 2013
Completion date	January 2015

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01005810` - A Trial of N-Acetylcysteine (an Over-the-Counter Medicine) in Adolescents Who Smoke Marijuana	Phase 2
Completed	`NCT00114439` - Lithium Cannabis Withdrawal Study	Phase 2
Completed	`NCT00350285` - The Teen Marijuana Check-Up	Phase 2
Completed	`NCT01618656` - Safety and Efficacy of a FAAH-Inhibitor to Treat Cannabis Withdrawal	Phase 2
Completed	`NCT01153490` - Improving Substance Use and Clinical Outcomes in Heavy Cannabis Users With Quetiapine	Phase 4
Completed	`NCT02946489` - Facilitating the Behavioral Treatment of Cannabis Use Disorder	Phase 1
Completed	`NCT02088177` - Study of Long-Acting Injectable Naltrexone to Treat Cannabis Dependence	Phase 1/Phase 2
Not yet recruiting	`NCT01565174` - The Pharmaco-genetic and Brain Mechanisms Associated With Cannabis- Induced Psychosis	N/A
Completed	`NCT01697709` - Quetiapine Pharmacotherapy for Cannabis Dependence	Phase 2
Recruiting	`NCT04721353` - Reducing Cannabis Overuse With Prazosin	Phase 4
Completed	`NCT01603992` - Quiting Marijuana Use: Self-report Study of Quitting Straegies and Withdrawal Symptoms
Completed	`NCT00167297` - Atomoxetine for the Treatment of Cannabis Dependence	Phase 2
Terminated	`NCT01598896` - Combination of Dronabinol and Clonidine for Cannabis Dependence in Patients With Schizophrenia	Phase 2/Phase 3
Completed	`NCT01611948` - Treatment for Cannabis Withdrawal and Dependence	Phase 2
Recruiting	`NCT03221231` - N-acetylcysteine for the Treatment of Cannabis Dependence: Working Mechanisms	Phase 4
Not yet recruiting	`NCT03366909` - Mindfulness Meditation and Cannabis Dependence : Therapy Effectiveness	N/A
Completed	`NCT01639872` - Clozapine for Cannabis Use in Schizophrenia	Phase 4
Not yet recruiting	`NCT06334016` - Evaluating the Delivery and Effects of THC Vaping Liquids in the Bloodstream	Early Phase 1
Completed	`NCT01793961` - Effects of Chronic Intake of Cannabis on Contrast Sensitivity	N/A
Completed	`NCT01747850` - Sativex and Behavioral-relapse Prevention Strategy in Cannabis Dependence	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.